Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Management change at ALK


Posted on: 31 Jul 17

Copenhagen, 2017-07-31 10:11 CEST (GLOBE NEWSWIRE) --  

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Flemming Pedersen, CFO and member of the Board of Management, has decided to resign his position and leave ALK to join a privately owned Danish company in another industry. 

Chairman of the Board of Directors, Steen Riisgaard, and President & CEO, Carsten Hellmann said: "We would like to offer our sincere thanks to Flemming for his strong contributions to ALK's development over the past seven years. We will miss him, but respect his decision to move on in his career." 

Flemming Pedersen said: "After seven inspiring and successful years with ALK, I have decided to join another company. ALK has become the undisputed leader in allergy immunotherapy and is now pursuing numerous exciting opportunities for further growth. While I am sad to leave ALK and will miss the many outstanding colleagues, partners and investors with whom I have the pleasure to work, I am also looking forward to my new challenge." 

Flemming Pedersen will leave ALK by 31 January 2018 at the latest. A search for a new CFO will now be initiated.
 

ALK-Abelló A/S

 

For further information please contact:
Carsten Hellmann, President & CEO
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014
 

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.

 

GlobeNewswire
globenewswire.com

Last updated on: 31/07/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.